GetTopicDetailResponse(id=fddf803043, topicName=GIP和GLP-1受體激動劑, introduction=GIP和GLP-1受體激動劑, content=null, image=null, comments=2, allHits=1417, url=https://h5.medsci.cn/topic?id=8030, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=90813, tagList=[TagDto(tagId=90813, tagName=GIP和GLP-1受體激動劑)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1379420, encodeId=3f1c13e94206c, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受體激動劑#</a>, objectTitle=Lancet：新型雙GIP和GLP-1受體激動劑單藥治療可以顯著改善糖尿病血糖和體重水平, objectType=article, longId=213906, objectId=58312139068b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58312139068b, replyNumber=0, likeNumber=104, createdTime=2021-07-09, rootId=0, userName=xre2008, userId=fd18451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58312139068b, moduleTitle=Lancet：新型雙GIP和GLP-1受體激動劑單藥治療可以顯著改善糖尿病血糖和體重水平, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=58312139068b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1379419, encodeId=526713e941950, content=<a href='/topic/show?id=fddf803043' target=_blank style='color:#2F92EE;'>#GIP和GLP-1受體激動劑#</a>, objectTitle=第79屆ADA：雙重GIP和GLP-1受體激動劑tirzepatide治療2型糖尿病的潛力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=97, createdTime=2019-06-11, rootId=0, userName=xre2008, userId=fd18451, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79屆ADA：雙重GIP和GLP-1受體激動劑tirzepatide治療2型糖尿病的潛力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
